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Abstract
Background: The role of neuroinflammation in motor neuron death of amyotrophic lateral sclerosis (ALS) is
unclear. The human mutant superoxide dismutase-1 (hmSOD1)-expressing murine transgenic model of ALS has
provided some insight into changes in microglia activity during disease progression. The purpose of this study was
to gain further knowledge by characterizing the immunological changes during disease progression in the spinal
cord and peripheral nerve using the more recently developed hmSOD1 rat transgenic model of ALS.
Methods: Using immunohistochemistry, the extent and intensity of tissue CD11b expression in spinal cord, lumbar
nerve roots, and sciatic nerve were evaluated in hmSOD1 rats that were pre-clinical, at clinical onset, and near disease
end-stage. Changes in CD11b expression were compared to the detection of MHC class II and CD68 microglial
activation markers in the ventral horn of the spinal cord, as well as to the changes in astrocytic GFAP expression.
Results: Our study reveals an accumulation of microglia/macrophages both in the spinal cord and peripheral nerve
prior to clinical onset based on CD11b tissue expression. The microglia formed focal aggregates in the ventral horn and
became more widespread as the disease progressed. Hypertrophic astrocytes were not prominent in the ventral horn
until after clinical onset, and the enhancement of GFAP did not have a strong correlation to increased CD11b
expression. Detection of MHC class II and CD68 expression was found in the ventral horn only after clinical onset. The
macrophages in the ventral nerve root and sciatic nerve of hmSOD1 rats were observed encircling axons.
Conclusions: These findings describe for the first time in the hmSOD1 rat transgenic model of ALS that
enhancement of microglia/macrophage activity occurs pre-clinically both in the peripheral nerve and in the spinal
cord. CD11b expression is shown to be a superior indicator for early immunological changes compared to other
microglia activation markers and astrogliosis. Furthermore, we suggest that the early activity of microglia/
macrophages is involved in the early phase of motor neuron degeneration and propose that studies involving
immunomodulation in hmSOD1transgenic models need to consider effects on macrophages in peripheral nerves
as well as to microglia in the spinal cord.
Background
In addition to motor neuron loss and paralysis, evidence
of reactive microglia/macrophages and astrocytes is
observed in motor regions of the CNS in sporadic and
familial amyotrophic lateral sclerosis (ALS) [1,2], as well
as in the ALS animal models of transgenic mice and
rats expressing human mutant SOD1 (hmSOD1) [3-7].
The role of the microglia and/or infiltrating macro-
phages in motor neuron degeneration has been difficult
to ascertain and is the focus of several reviews [8,9].
Although administration of immunosuppressive drugs
early in disease development has extended survival in
the transgenic mouse model of ALS [10-12], such treat-
ment has not been successful in clinical trials for ALS
to date [13-17].
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been identified early in disease development in spinal
cord tissues from hmSOD1 transgenic mice and rats
[18-21]. Onset and progression of reactive microglia or
infiltrating macrophages have also been reported pre-
viously. Microglia identified with CD11b, a constitutive
marker of myeloid cells, are increased at clinical onset
and increase further by disease end-stage in the
hmSOD1 murine model [6,22]. The extent of CD11b
expression is also elevated in the hmSOD1 rat model
even prior to clinical onset [5]. Cells expressing MHC
class II occur after clinical onset in hmSOD1 mice [3],
whereas induction of CD68 expression has been
reported pre-clinically [23]. The onset of various micro-
glial activation markers has not been fully explored in
the rat model or altogether throughout disease
progression.
Although gliosis is well documented along with neuro-
degeneration in the CNS, motor axons in the peripheral
nervous system (PNS) are also lost early in disease
development [24-26]. Accumulation of macrophages in
sciatic nerve and ventral nerve root has been described
when the murine hmSOD1 model was initially devel-
oped [25], but little is known regarding their progression
or their occurrence in the rat model.
Using the hmSOD1 transgenic rat model of ALS, we
investigate the progression of reactive microglia in the
spinal cord and macrophage activity in the PNS. We
describe for the first time in the rat model that in addi-
tion to the early enhancement of microglial CD11b
expression in the ventral horn, macrophages accumulate
in the ventral nerve root and sciatic nerve pre-clinically.
Also, astrogliosis and other microglia activation markers
(MHC class II and CD68) occur in the ventral horn
later in disease development relative to the enhance-
ment of CD11b expression.
Methods
Animals
Hemizygous hmSOD1 (G93A, L26H line) rats on a
Sprague-Dawley background were obtained from Taco-
nic Farms (Germantown, NY). The Institutional Animal
Care and Use Committee at Dartmouth College
approved all experimental protocols. The colony was
subsequently maintained by breeding hmSOD1 male
rats with wild-type Sprague-Dawley females. About one
half of the offspring carried the SOD1 mutation; they
were identified at three weeks of age by genotyping for
human SOD1 with tissue from ear punches that was
digested overnight at 55°C in 200 μlD i r e c t P C Rl y s i s
reagent (Viagen Biotech Inc., Los Angeles, CA) contain-
ing 2 mg/ml of proteinase K (Roche Diagnostics, Iniana-
polis, IN). Solutions were vortexed, heated at 85°C for
45 min, and 1 μl was added to a PCR mastermix
containing water (9.5 μl), 10× buffer (2 μl), Q (4 μl),
dNTP (0.4 μl), 20 μM forward and reverse primers (1 μl
each), and TAQ (1 μl). Positive bands were detected
with ethidium bromide on 1% agarose electrophoresis
gels that were run with confirmed positive and negative
hmSOD1 controls. Rat GAPDH primer served as a
control.
Animals were allowed to feed ad libitum with two or
three rats per cage, and both water and food were
always within reach of animals through to end-stage of
disease. Weighing and scoring of motor deficits were
performed by an examiner blinded to the genotype of
the animals. Weights were recorded twice per week
before 90 days of age and then four times per week
thereafter. Gait and limb paralysis was assessed for all
animals during weighing sessions and each limb was
recorded as having paresis (limping with limited range
of motion) or paralysis (no movement). Each rat was
assigned a score based on the number and state of
affected limbs as shown in Table 1 (unpublished scoring
developed by D. Howland, Wyeth Research, Princeton,
New Jersey). Tissues were collected from hmSOD1 rats
and assessed based on age or categorized into four dis-
ease stages (Table 2): 1) early pre-clinical; 2) late pre-
clinical; 3) clinical onset (normal gait, but stopped gain-
ing weight) 4) disease end-stage (limb paralysis and 20%
loss in maximum weight ). Tissues from age-matched
wild-type littermates were also collected.
Immunohistochemistry
Cervical-thoracic and lumbar segments of spinal cord
that were approximately 2 cm in length and both sciatic
nerves were rapidly dissected from hmSOD1 and wild-
type rats ranging from 60 to 130 days of age following
CO2 euthanasia. Spinal cords were prepared for
Table 1 Limb paralysis scoring of hmSOD1 rats
score Number of Affected Limbs Limb Phenotype
8 0 normal gait and range of motion
7 1 paresis
6 1 paralysis
2 paresis
5 2 1 paresis, 1 paralysis
3 paresis
4 2 paralysis
3 2 paresis, 1 paralysis
3 3 1 paresis, 2 paralysis
4 3 paresis, 1 paralysis
2 3 paralysis
4 2 paresis, 2 paralysis
1 4 1 paresis, 3 paralysis
0 4 paralysis
Scoring criteria of motor impairment in hmSOD1 rats based on detection of
limb paresis (limited movement) and paralysis (no movement).
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zen tissues were submerged in OCT-embedding med-
ium (Sakura, Tokyo, Japan) for 5 min, then snap-frozen
and stored at -80°C. (2) Paraformaldehyde-immersed tis-
sues were immediately fixed in 4% buffered paraformal-
d e h y d ef o r2ha t4 ° C ,r i n s e dw i t hP B S ,a n ds t o r e d
overnight in 30% sucrose solution. These tissues were
then immersed in room temperature OCT for 15 min,
then rapidly frozen, and stored at -80°C. Spinal cords
segments from similarly aged hmSOD1 and wild-type
rats were embedded within the same OCT sectioning
block. Seven-micron thick transverse-sections were cut
with a cryostat microtome (Leica Microsystems, Deer-
field, IL) and mounted on Superfrost/Plus microscope
slides (Thermo Fisher Scientific, Waltham, MA). Fresh-
frozen sections were immediately fixed in cryostat tem-
perature methanol for one minute and subsequent steps
were performed in 0.5 M Tris-HCl buffer. Paraformalde-
hyde -immersed sections involved no further fixation
and were performed in 0.1 M PBS. Blocking and subse-
quent antibody solutions contained 1% bovine serum
albumin and 1% normal serum from goat or fetal
bovine. Sections were treated with primary antibodies
overnight at 4°C. Tissue sections without primary anti-
body were used to control for background staining.
Microglia and macrophages were labeled with mouse
anti-CD11b (OX-42 supernatant). The OX-42 antibody
to rat CD11b is superior relative to antibodies to murine
CD11b. Rabbit anti-Iba1 (1:650; Wako Chemicals USA,
Richmond, VA), mouse anti-CD68 (ED1; 1:300; Serotec,
Raleigh, NC), and MHC class II (OX-6 supernatant)
were also used to label microglia/macrophages. Astro-
cytes were labeled with rabbit anti-GFAP (1:600; Dako,
Carpinteria, CA). Neurons were labeled with mouse
anti-NeuN (1:10,000; Millipore, Billerica, MA) or rabbit
anti-bIII-tubulin (1:2000; Millipore). Schwann cells were
labeled with rabbit anti-S100 (1:200; Sigma-Aldrich, St.
Louis, MO).
For diaminobenzidine (DAB)-stained sections, samples
were incubated for one hour with biotinylated horse
anti-mouse antibody (1:80; Vector Laboratories,
Burlingame, CA). Slides were rinsed and then incubated
for 15 min with 5% hydrogen peroxide in methanol
(fresh-frozen) or PBS (paraformaldehyde -immersed).
Sections were rinsed and stored in ABC solution (Vector
Laboratories) for 90 min. After rinsing, sections were
labeled with 1 mg/ml DAB (Sigma-Aldrich) containing
10 mM imidazole and 0.03% hydrogen peroxide for ten
minutes. Slides were rinsed, dehydrated, and cover-
slipped using Permount (Fisher Scientific) mounting
medium.
For fluorescence-labeled sections, goat anti-mouse
IgG1 (1:200), goat anti-mouse IgG2a (1:200), goat anti-
mouse IgG (1:300), and/or goat anti-rabbit IgG conju-
gated to Alexa 568, Alexa 594, or Alexa 488 (Invitrogen,
Carlsbad, CA) were applied to the sections for two
hours at 37°C. Slides were rinsed and coverslips affixed
with Vectashield (Vector Laboratories) mounting media
supplemented with 4’,6-diamidino-2-phenylindole (1 μg/
ml, Sigma-Aldrich), and finally sealed with nail-polish.
Image analysis and statistics
Images were taken using a Hamamatsu (model C4742-
95) or PixeLink (model PL-A662) digital camera
mounted on a wide-field fluorescence (Zeiss Axiophot)
or on a bright-field (Nikon Diophot-TMD) microscope.
Exposure times and magnification were kept constant
among comparison groups. Quantification of grey-scale
image files was performed using IPLab 3.6.5 software
(Scanalytics, Inc. Fairfax, VA). Immunohistochemical
staining was highlighted by setting the grey-level detec-
tion limits to a constant threshold, and the area of high-
lighted immunoreactivity was calculated as percent of
total area (extent) and average signal intensity of the
selected field. Tissues from hmSOD1 rats were com-
pared directly to similar regions from wild-type rats that
were immunostained together on the same slide to
reduce technical variability.
For quantification of DAB-stained CD11b expression,
between 20 and 30 total tissue sections of each spinal
cord region were averaged together from each disease
stage; between 13 and 23 total cross-section samples of
nerves were averaged together per disease stage. The
Table 2 Details of hmSOD1 rats per disease stages
Disease Stage Number of
Animals
(male, female)
Average Age in Days +/-
SD
Average Recent Weight Change* in g/day
+/- SD
Average Motor Score** +/-
SD
Early Pre-
Clinical
4 (3,1) 70.5 +/- 6.6 3.2 +/- 1.5 8
Late Pre-
Clinical
5 (4,1) 90.8 +/- 1.6 2.7 +/- 0.9 8
Clinical Onset 5 (4,1) 105.2 +/- 5.0 -0.3 +/- 1.0 8
End-Stage 6 (4,2) 119.5 +/- 5.5 -10.0 +/- 3.9 3.5 +/- 1.0
Number, age, and clinical phenotype of hmSOD1 rats in each disease stage that were used for histological analysis. SD represents standard deviation. *Recent
Weight change was recorded over a 10 day period. **See Table 1 for criteria of motor scoring.
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2 for
ventral horn, 0.258 mm
2 for ventral white matter, 0.213
mm
2 for dorsal horn, 0.121 mm
2 for ventral nerve root,
0.150 mm
2 for dorsal nerve root, and 0.209 mm
2 for
sciatic nerve.
For quantification of GFAP and CD11b expression
with dual immunofluorescence in the lumbar spinal
cord, between 6 and 9 different ventral horn regions
were averaged together per disease stage. The average
area evaluated within the ventral horn was 0.145 mm
2.
Extent and intensity levels were expressed as a fold-
change with respect to averaged values measured in
wild-type tissue. A Newman-Keuls test following an
ANOVA analysis was used to determine significance
among various disease stages from hmSOD1 tissues and
wild-type tissues. A student t-test was performed to
determine significance between hmSOD1 tissue from a
specific disease stage and age-matched wild-type tissue.
A p-value of less than 0.05 was considered significant.
Results
Clinical progression in hmSOD1 rat
All hmSOD1 rats used in this study lost weight and had
limb paralysis before 130 days of age while wild-type lit-
termates continued to gain weight and never exhibited
paresis or paralysis (Fig. 1A-C). Prior to 95 days of age,
hmSOD1 rats gained weight at a similar rate as age-
and sex-matched wild-type littermates (Fig. 1A). The
onset of weight loss and development of limb paralysis
occurred variably at ages 95-116 and 106-118 days,
respectively (Fig. 1A-C). Limb paralysis presented either
in a forelimb (2/7), hind limb (4/7), or simultaneously in
a fore- and hind limb (1/7). Onset of weight loss pre-
ceded the first sign of limb paralysis by an average of 11
days (Fig. 1D). For this study, disease stages were based
on weight change and detection of limb motor impair-
ment as shown in Table 2.
Change in CD11b expression in spinal cord
Microglia were assessed in spinal cords for changes in
extent (occupied area) and intensity (average signal
intensity) of CD11b expression. In wild-type littermates,
microglia occupied 3.2% and 1.1% of the total tissue
area within the ventral horn and ventral white matter,
respectively, throughout the spinal cord. In hmSOD1
rats, the extent of CD11b expression increased in the
ventral horn and white matter with age (Figs. 2B,C and
3A,B). In early pre-clinical hmSOD1 rat, there was a 72
+/- 32% increase in the extent of expression relative to
wild-type tissue in the ventral horn with no significant
change in the adjacent white matter region. In late pre-
clinical hmSOD1 rat, there was a 297 +/- 50% increase
in the ventral horn and a 40 +/- 10% increase in the
ventral white matter (Figs. 2B and 3C). A significant
increase in average tissue intensity of CD11b expression
Figure 1 Clinical onset and progression of disease. Weight loss
and limb motor abnormalities in hmSOD1 transgenic rats as a
function of age. (A) Weight in grams of male hmSOD1 (black) and
wild-type littermates (gray). (B) Weight expressed as percent of
maximum recorded weight in male (black) and female (gray)
hmSOD1 rats. (C) Limb paralysis motor score of male (black) and
female (gray) hmSOD1 rats. See Table 1 for scoring criteria. (D)
Average time between age of onset for weight loss and limb
paralysis relative to disease end-stage in hmSOD1 rats. *,
significantly different (P < 0.01, paired T test).
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tral horn (6.0 +/- 0.9%) in late pre-clinical hmSOD1 rat
and in the ventral white matter (2.5 +/- 0.6%) during
clinical onset (Fig. 3D). The extent and intensity of
CD11b expression increased further as age and disease
progressed (Fig. 2B,C and 3A-D). No changes in CD11b
expression were measured in the dorsal horn until dis-
ease end-stage (Fig. 3C,D).
Changes in CD11b expression in nerve root and sciatic
nerve
Only a few CD11b-postive resident macrophages were
observed in nerve roots (0.25% of tissue area) and sciatic
nerves (0.58% of tissue area) from wild-type rats (Fig.
2D,F). In hmSOD1 rats, the extent of CD11b expression
increased in the ventral nerve roots and sciatic nerves
with age and disease progression (Fig. 2E,G and 4A-C).
In late pre-clinical hmSOD1 rat, the extent of CD11b
expression increased 189 +/- 55% in the ventral nerve
root and 236% +/- 59% in the sciatic nerve relative to
wild-type levels (Fig. 4C). No change in CD11b expres-
sion was measured in the dorsal nerve roots throughout
the course of disease (Fig. 4C).
Correlation of CD11b and GFAP expression in ventral
horn
GFAP-labeled astrocytes in the ventral horn of hmSOD1
rats were hypertrophic during later clinical stages of dis-
ease development, but not pre-clinically (Fig. 5A,B).
While increased extent and intensity of CD11b expres-
sion revealed a strong positive logarithmic correlation
(r
2 = 0.72) throughout disease progression, the extent
and intensity of GFAP expression did not correlate (Fig.
6A,B). There was a moderate linear correlation (r
2 =
0.52) between increased extent of CD11b and GFAP
expression (Fig. 6C), but not between tissue intensity of
CD11b and GFAP (Fig. 6D).
Microglia aggregate in the ventral horns prior to clinical
onset
Microglia in the ventral horns of pre-clinical hmSOD1
rats were typically found in focal aggregates that were
identified with CD11b (Fig. 2B and 5A) or Iba1 (Fig. 5C)
markers. GFAP-labeled astrocytes did not cluster
together in the ventral horns early in disease (Fig. 5A)
and remained relatively dispersed at disease end-stage
(Fig. 5B). The intracellular labeling of Iba1 and nuclear
counterstain revealed a dense clustering pattern for the
microglia (Fig. 5C). These early focal clusters of micro-
glia were often near, but rarely juxtaposed and never
observed fully encapsulating NeuN-labeled motor neu-
rons (Fig. 5C). Activation markers CD68 and MHC class
II were observed in ventral horns of hmSOD1 rats after
clinical onset (Fig. 7D-F), but were not remarkably
expressed in pre-clinical rats even at sites of the focally
elevated CD11b expression (Fig. 7A-C).
Macrophages in nerve root and sciatic nerve
The CD11b-labeled macrophages seen in ventral nerve
root and sciatic nerve from hmSOD1 rats typically
formed ring-like morphologies in pre-clinical hmSOD1
rats through to disease end-stage (Figs. 2E,G, 5D,E, and
7G). Co-labeling of CD11b and bIII-tubulin in ventral
nerve after clinical onset revealed many macrophages to
be partially encompassing individual nerve fibers or
forming complete ring-shapes at sites devoid of a bIII-
tubulin-labeled axon (Fig. 5D). Co-labeling of CD11b
and S100 showed the overall tissue architecture of
Schwann cells remained relatively unperturbed at end-
stage disease, while the macrophages were often juxta-
posed between them and the axon (Fig. 5E). The nerve
macrophages in hmSOD1 rats expressed the macro-
phage marker CD68, but seldom expressed MHC class
II (Figs. 7G,I).
Discussion
It is clear that microglia and macrophages are involved
in the pathological processes of ALS and in the
hmSOD1 transgenic animal models of the disease. What
is uncertain is their role in pathogenesis and during the
evolving pathophysiological process. Further understand-
ing of their changes with respect to disease development
is essential and may provide insight into their participa-
tion in motor neuron death. In this study, we evaluated
spinal microglia and macrophages in the PNS before
and after clinical manifestation in the transgenic
hmSOD1 (G93A) rat based primarily on the changes in
tissue expression of CD11b. This increasingly used
transgenic animal model of ALS is relatively new and
has not been as well characterized with regard to neu-
roinflammation and glial activation as the murine trans-
genic model. We show that microglia/macrophages are
active early in the disease process both in the ventral
horn where the soma of lower motor neurons reside
and along the path of their axons in the adjacent ventro-
lateral white matter region and peripheral nerve.
The hmSOD1 rats used in this study were categorized
as being pre-clinical, at clinical onset, or near disease
end-stage. Since a loss in weight gain preceded the
onset of limb paralysis, which has also been documented
i nas e p a r a t et r a n s g e n i cl i n eo fh m S O D 1r a t[ 2 7 ] ,
reduced rate of weight change was used to distinguish
between pre-clinical and clinical onset. Weight loss is
also an early clinical presentation in the murine model
and precedes more sensitive detections of motor dys-
function such as the paw grip endurance test [28]. The
average age of pre-clinical rats used in this analysis was
more than two weeks earlier than that the average age
of clinical onset. Limb paralysis was not yet present in
rats classified as at clinical onset.
Graber et al. Journal of Neuroinflammation 2010, 7:8
http://www.jneuroinflammation.com/content/7/1/8
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ment of CD11b tissue expression and the formation of
microglia in focal aggregates were observed. Atypical
clusters of microglia have been described previously as
the cells fusing together to form multinucleated giant
cells of the Langhans type following clinical onset [5]. It
is difficult to prove that the microglia have fused and
formed giant cells based on immunohistochemical ana-
lysis alone, but the cytological appearance of irregular
plasmalemma borders and haphazard arrangement of
nuclei suggests that they are individual cells aggregating
rather than fused giant cells. The microglia may be
targeting degenerating neurons and in a process of neu-
ronophagia in which phagocytes engulf a dying neuron.
However, we only found occasional neurons partially
encompassed by these formations at the pre-clinical
stage, and did not find neurons fully encircled. It is
plausible that at the time of neuronophagia the neuron
had degenerated to an extent that it no longer was iden-
tifiable with a marker such as NeuN. Yet, it is also
important to note that the activation markers CD68 and
MHC class II, which are normally upregulated in micro-
glia during phagocytosis [29-32], did not co-localize
with these formations at pre-clinical stage of disease.
Figure 2 CD11b-labeld microglia/macrophages in spinal cord and nerve. Microglia or macrophages in the ventral spinal cord, ventral nerve
roots, and sciatic nerve as assessed by CD11b histological expression. (A) CD11b-labeled microglia are evenly distributed in the ventral horn (VH,
above dashed line) and in the ventral white matter (WM, below dashed line) of wild-type rats. (B) In pre-clinical hmSOD1 rats, focal increases in
CD11b expression are often observed in the ventral horn. (C) After clinical onset, the extent of CD11b expression increases in ventral horn and
to a lesser degree in the adjacent ventral white matter. Scale bar in panel A represents 200 μm for A-C. (D) There are very few CD11b-labeled
resident macrophages in ventral nerve roots of wild-type rats. (E) After clinical onset in hmSOD1 rats, there is an increase in macrophages in the
ventral nerve root. Scale bar in panel D represents 100 μm for D and E. (F) Very few CD11b-labeled resident macrophages are found in sciatic
nerve of wild-type rats. (G) After clinical onset in hmSOD1 rats, there is an increase in macrophages in the sciatic nerve. Scale bar in panel F
represents 100 μm for F and G.
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dying neuron but rather an unidentified extra-neuronal
stimulus such as aggregates of mutant SOD1 protein or
paracrine signals from cytokines or other secreted mole-
cules. These clusters of microglia may then secondarily
cause damage to nearby motor neurons. Increased
mRNA for IL-1b, IL-12, MIPa,b,T G F - b,a n dT N F - a
have been reported in the hmSOD1 rat at pre-clinical
stage of disease [20]. These changes in cytokine
Figure 3 Regional changes in CD11b expression in spinal cord.
Changes in the extent and intensity of DAB-stained CD11b
expression in spinal cord of hmSOD1 rats as a function of age or
disease stage. (A, B) The extent of CD11b expression relative to age-
matched wild-type levels is expressed as a function of age. Linear
regression slopes in the ventral horns of 0.12 ± 0.018 at the
cervical-thoracic level and 0.15 ± 0.028 at the lumbar level (A).
Linear regression slopes in the ventrolateral white matter are 0.05 ±
0.011 at the cervical-thoracic level and 0.069 ± 0.0107 at the lumbar
level (B). (C, D) The average extent (C) and intensity (D) of CD11b
expression relative to wild-type levels in spinal cord regions
expressed as a function of disease stage. Bars represent average +
SEM. #, significantly different compared to wild-type levels (P <5×
10
-5, Neuman-Keuls test). *, significantly different compared to levels
from only age-matched wild-type rats (P < 0.05, unpaired T test).
Figure 4 Changes in CD11b expression in nerve roots and
sciatic nerve. Changes in the extent of DAB-stained CD11b
expression in lumbar nerve roots and sciatic nerves of hmSOD1 rats.
(A,B) The extent of CD11b expression relative to age-matched wild-
type levels is expressed as a function of age. Linear regression
slopes are 1.7 ± 0.45 in the ventral nerve roots (A) and 0.21 ± 0.063
in the sciatic nerve (B). (C) The average extent of CD11b expression
relative to wild-type levels is expressed as a function of disease
stage. Bars represent average + SEM. ND, not determined. #,
significantly different compared to wild-type levels (P < 0.0005,
Neuman-Keuls test). *, significantly different compared to levels from
only age-matched wild-type rats (P < 0.05, unpaired T test).
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Page 7 of 12Figure 5 Microglia/macrophages with neurons, astrocytes, and Schwann cells. Dual immunofluorescence of microglia in the ventral horn
and macrophages in the ventral nerve root of hmSOD1 rat. (A,B) GFAP-labeled astrocytes (green) and CD11b-labeled microglia (red) in a ventral
horn at pre-clinical stage (A) and after clinical onset (B). Scale bar in panel A represents 100 μm for A and B. (C) Composite image showing Iba1-
labeled microglia (red) near NeuN-labeled motor neurons (green) in a pre-clinical rat. Scale bar in panel C represents 200 μm. (D,E) CD11b-
labeled macrophages (red) relative to bIII-tubulin-labeled axons (D, green) or S100-labeled Schwann cells in ventral nerve root after clinical onset
(E, green). Scale bar in D represents 100 μm for D and E.
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aggregating microglia. Further analysis is needed to
determine what role these clusters of microglia have in
the neurodegeneration process.
Pre-clinical rats also showed an increase of microglia
in the ventrolateral white matter, where lower motor
neuron axons are known to cross, and an increase in
macrophages in the ventral (motor) nerve root and in
the sciatic nerve. No macrophage accumulation
occurred in the dorsal (sensory) nerve root indicating a
specific association of macrophage changes with lower
motor neuron axons. Dal Canto and Gurney identified
macrophages in the PNS of transgenic hmSOD1 mice
using electron microscopy when the animal model was
initially developed [25], but more descriptive data on
this phenomenon has been lacking to date. Resident
macrophages comprise less than five percent of the cell
population of the peripheral nerve [33]. They express
several macrophage antigens including CD11b, CD68,
and MHC class II [34]. The accumulated macrophages
in the hmSOD1 peripheral nerve expressed CD11b and
CD68, but only few of these cells expressed MHC class
II. This is similar to what is observed following nerve
injury model [34,35]. The macrophages in the hmSOD1
nerve appeared as rings formed around individual axons,
which is also similar to the response after nerve injury
[35,36]. In the murine hmSOD1 model, activation of
Schwann cells in the peripheral nerve prior to clinical
onset has been reported based on increased GFAP
expression [37]. This activation of Schwann cells in
addition to our observation of increased macrophages in
the nerves of hmSOD1 rats might indicate a response to
Wallerian degeneration associated with dying-back of
motor axons that has been described previously in the
mouse model [24]. Although increased macrophages
were detected pre-clinically in both the ventral nerve
root and more distally at the sciatic nerve, it would be
important to know when or if macrophages accumulate
closer to the neuromuscular junction in nerves distal to
the branching of the sciatic nerve. It cannot be ruled
out that these macrophages are responding to an uni-
dentified stimulus or that they contribute to axonal
damage. Further investigation is warranted.
As rats progressed to clinical onset and even further
to disease end-stage, the accumulation of microglia/
macrophages increased further in the ventral horn, the
adjacent white matter region, ventral nerve root, and
sciatic nerve. Within the ventral horn, hypertrophic
astrocytes were now present. This timing of increased
astrocyte activity supports previous findings in the mur-
ine model [3,37], although Keller and colleagues
observed temporary increases at earlier stages using live
imaging analysis. Surprisingly, the increase in the extent
or intensity of astrocytic GFAP tissue expression did not
Figure 6 Correlation between CD11b and GFAP expression in
ventral horn. Changes in GFAP and CD11b in lumbar ventral horn
detected with dual immunofluorescence throughout disease
progression. (A,B) The extent relative to intensity of CD11b (A) and
GFAP (B) expression. (C) The extent of expression of CD11b relative
to GFAP expression. (D) The tissue intensity of CD11b relative to
GFAP expression.
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Page 9 of 12Figure 7 Expression of CD11b, CD68, and MHC class II in spinal cord and ventral nerve root. Expression of CD11b, CD68, and MHC II in
adjacent sections of ventral spinal cord and ventral nerve root of hmSOD1 rats. (A-C) In pre-clinical stage ventral horn, a cluster of CD11b-
labeled microglia (A) in the ventral horn (VH, above dashed line) does not co-localize with CD68 (B) or MHC II (C). (D-F) In the ventral horn after
clinical onset, CD11b expression (D) is more widespread and both CD68 (E) and MHC II (F) expression are detected. (G-I) In ventral nerve root
after clinical onset, both CD11b- (G) and CD68-labeled (H) cells are increased, but MHC II-labeled cells (I) remain sparse. Scale bar in panel A
represents 200 μm for all panels.
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Page 10 of 12have a strong correlation with increases in microglial
CD11b expression within the same tissue samples. We
propose that microglial activation based on CD11b
expression, not astrocytic activation, is a superior histo-
logical marker for disease progression in the rat trans-
genic model of ALS.
Microglial activation markers MHC class II and
CD68 appeared in a subpopulation of cells after clini-
cal onset in the ventral horn as the extent and inten-
sity of CD11b tissue expression continued to increase.
For MHC class II, this stage of detection is similar to
its onset in the murine model [3]. Several studies
reported CD68 expression in the ventral horn in late
stages of disease development [23,38,39]. Few CD68-
positive cells were detected at pre-clinical stages in the
murine model that had become widespread throughout
the ventral horn at later stages [23]. Also in the mur-
ine model, mRNA levels of CD68 have been shown to
be elevated just prior to clinical onset and then
increased further as disease progressed [21,23]. We did
not find remarkable CD68 expression until after clini-
cal onset in the rat model and it never was as wide-
spread relative to the CD11b expression. The
expression pattern we observed was more punctuate,
likely representing lysosomal and not plasma mem-
brane expression, relative to the murine model. The
discrepancies in the onset of CD68 expression and pat-
tern of cellular expression between the rat and mouse
model might have to do with the different antibodies
used, which are species specific and may bind different
isoforms or glycosylation states of CD68.
In hmSOD1 mice, pre-clinical administration of
immunosuppressive drugs prolonged survival [10-12],
while a separate study reported that continually ablated
proliferating microglia in lumbar spinal cord beginning
close to clinical onset resulted in decreased microgliosis
without protection of motor neurons [22]. Interestingly,
modulating microglia activity by eliminating functional
T lymphocytes in the murine hmSOD1 model of ALS
decreased mRNA levels of CD68 and increased levels of
TNF-a and NOX2, which lead to a shorter survival
duration without any change in time of onset [40,41].
Although CD11b expression was increased prior to clin-
ical onset in our study, other microglia activation mar-
kers (CD68 and MHC class II) and astrogliosis were
detected in the ventral horn after clinical onset. Taken
together, we suggest that the immunological activity
occurring prior to clinical onset is involved in the induc-
tion of motor neuron degeneration, whereas the activity
observed after clinical onset is more involved with other
cell functions such as clearing the debris of degenerated
neurons.
Conclusion
In summary, this immunohistochemical investigation of
the rat transgenic model of ALS describes the early
accumulation of microglia occurring in the ventral horn
and in adjacent white matter, and macrophages in the
ventral nerve root and sciatic nerve, corresponding with
the path of the soma and axon of lower motor neurons.
The macrophage activity occurring in the nerves needs
to be taking into account in studies involving immuno-
modulation in transgenic animal models of ALS. We
propose that the pathophysiological immune activity is
different before and after clinical onset of disease.
Further understanding of the microglia/macrophage
activity occurring prior to clinical onset may shed light
on the unresolved mechanism of neurodegeneration and
lead to more targeted immunomodulation therapies that
are effective in stopping neuron loss in ALS.
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